The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
暂无分享,去创建一个
Yih-Leong Chang | J. Shih | Pan‐Chyr Yang | J. Yang | Yi-nan Liu | Chong-Jen Yu | Shang-Gin Wu | Meng-Feng Tsai | Yueh-Feng Wen
[1] D. Gerber,et al. Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[3] J. Neal,et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.
[4] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[5] L. Sequist,et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. , 2015, The Lancet. Oncology.
[6] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[7] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.
[8] E. Smit,et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. , 2014, Lung cancer.
[9] Kazutaka Nakashima,et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor , 2014, OncoTarget.
[10] Yi-long Wu,et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[11] K. Kunimasa,et al. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor , 2013, Cancer.
[12] J. Shih,et al. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. , 2013, Lung cancer.
[13] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Ladanyi,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[15] C. Klein,et al. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.
[16] J. Shih,et al. Survival of lung adenocarcinoma patients with malignant pleural effusion , 2012, European Respiratory Journal.
[17] William Pao,et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 , 2012, Proceedings of the National Academy of Sciences.
[18] K. Kunimasa,et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations. , 2012 .
[19] Yan Sun,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.
[20] Youngwook Kim,et al. The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor , 2012, Molecular Cancer Therapeutics.
[21] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[22] J. Shih,et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer , 2011, European Respiratory Journal.
[23] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[24] J. Austin,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] William Pao,et al. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation , 2010, Clinical Cancer Research.
[26] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[27] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[29] J. Abbruzzese,et al. F1000 highlights , 2009, JAMA.
[30] A. Malarcher,et al. Cigarette Smoking Among Adults in the United States , 2008 .
[31] M. Ladanyi,et al. Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma , 2008, Clinical Cancer Research.
[32] J. Shih,et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma , 2008, European Respiratory Journal.
[33] C. Husten,et al. Cigarette smoking among adults--United States, 2006. , 2007, MMWR. Morbidity and mortality weekly report.
[34] D. Tenen,et al. BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations , 2007, PLoS medicine.
[35] S. Toyooka,et al. The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor , 2007, Clinical Cancer Research.
[36] William Pao,et al. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.
[37] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[38] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[39] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[40] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[41] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[42] S. Toyooka,et al. The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor. Authors' reply , 2007 .
[43] C. Husten,et al. Cigarette Smoking Among Adults, United States , 2006 .